Current therapy of CML involves five approved TKIs that are used according to risk, disease stage, co-morbidities and BCR-ABL1 genotype, reflecting the high level of personalization that has already been achieved in this disease. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.